CHRISTIE BALLANTYNE to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Randomized Controlled Trials as Topic.
Connection Strength
0.868
-
HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 05 02; 390(17):1622-1623.
Score: 0.146
-
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
Score: 0.100
-
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
Score: 0.079
-
Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
Score: 0.062
-
Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
Score: 0.054
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.040
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
Score: 0.040
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.037
-
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
Score: 0.034
-
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 01 18; 79(2):220-222.
Score: 0.031
-
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
Score: 0.031
-
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020 Sep - Oct; 14(5):649-659.e6.
Score: 0.028
-
Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
Score: 0.027
-
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
Score: 0.023
-
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
Score: 0.022
-
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
Score: 0.022
-
Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. PLoS One. 2014; 9(3):e92469.
Score: 0.018
-
Coronary artery bypass graft surgery remains the standard of care for patients with diabetes. Semin Thorac Cardiovasc Surg. 2013; 25(2):97-9.
Score: 0.017
-
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010 Jul; 3(4):398-404.
Score: 0.014
-
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 Feb 01; 103(3):369-74.
Score: 0.013
-
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 Aug; 23(8):2009-26.
Score: 0.011
-
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
Score: 0.011
-
A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
Score: 0.007